<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01409681</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2010.105</org_study_id>
    <secondary_id>HUM 44333</secondary_id>
    <nct_id>NCT01409681</nct_id>
  </id_info>
  <brief_title>A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung Cancer</brief_title>
  <acronym>EBUS</acronym>
  <official_title>A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D exerts antiproliferative and differentiating effects in cancers, including&#xD;
      non-small cell lung cancer (NSCLC). The active form of Vitamin D is 1,25,&#xD;
      dihydroxycholecalciferol (calcitriol) which rapidly induces expression of cytochrome P450&#xD;
      24R-hydroxylase (CYP24A1). CYP24A1 initiates inactivation of calcitriol as a result of&#xD;
      successive hydroxylation/oxidation reactions. This study seeks to prospectively determine the&#xD;
      relationship between Vitamin D gene expression and median survival as a primary outcome, and&#xD;
      between the Vitamin D receptor (VDR)/CYP24A1 gene expression and cancer stage, smoking&#xD;
      status, serum 1,25 (OH)2D3 levels as well as CYP24A1 genotype.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study seeks to prospectively determine the relationship between Vitamin D gene&#xD;
      expression and median survival as a primary outcome, and the relationships between the&#xD;
      Vitamin D receptor (VDR)/CYP24A1 gene expression and cancer stage, smoking status, serum 1,25&#xD;
      (OH)2D3 levels as well as CYP24A1 genotype.&#xD;
&#xD;
      Patients who are suspected to have lung cancer will be recruited to this study prior to their&#xD;
      diagnostic biopsy. Those who have consented to the study will give permission for blood and&#xD;
      tissue from this biopsy to be analyzed for the study endpoints. Statistical analysis on this&#xD;
      data will seek to correlate CYP24A1 expression and medican survival of the participants.&#xD;
      Patients' data will be collected for smoking status and cancer stage.&#xD;
&#xD;
      Study enrollment to adequately power the study statistically is 80 patients. Anticipated&#xD;
      study duration is from 12 months to 18 months for sample collection and two years for&#xD;
      follow-up for patient survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI decided to terminate the study&#xD;
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to lung cancer related death</measure>
    <time_frame>18 months</time_frame>
    <description>Time to lung cancer related death</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">41</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Observational Group</arm_group_label>
    <description>NSCLC subject undergoing bronchoscopy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bronchial brush samples Bronchoscopy samples for RNA extraction and RT-PCR expression Blood&#xD;
      samples&#xD;
&#xD;
        -  7 mL for measurement of Serum total Vit-D levels and 1,25 (OH)2 D3 levels;&#xD;
&#xD;
        -  5 ml collected in EDTA tube for CYP24A1 genotype analysis (common metabolizing agent for&#xD;
           calcitriol) and CYP24 polymorphisms analysis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with early-stage non-small cell lung cancer undergoing a broncoscopy at the&#xD;
        University of Michigan Health Center or at the Ann Arbor Veteran's Administration Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Scheduled for diagnostic bronchoscopy for suspected advanced stage lung cancer by&#xD;
             CT/PET scanning.&#xD;
&#xD;
          2. Tumor or lymph node accessible by transbronchial needle aspiration.&#xD;
&#xD;
          3. Age 18-80.&#xD;
&#xD;
          4. All patients must be informed of the investigational nature of this study and must&#xD;
             give written informed consent in accordance with institutional and federal guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unstable cardiovascular disease or other systemic disease&#xD;
&#xD;
          2. Mental incompetence/active psychiatric illness&#xD;
&#xD;
          3. Medical contraindication for bronchoscopy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nithya Ramnath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Medical Center and Veteran's Administration Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>United States Department of Veteran's Affairs Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>July 22, 2011</study_first_submitted>
  <study_first_submitted_qc>August 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <last_update_submitted>March 28, 2014</last_update_submitted>
  <last_update_submitted_qc>March 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

